Vice-president of global public health and tuberculosis, Johnson & Johnson
Cat Oyler serves as vice-president of global public health (GPH) at Johnson & Johnson (J&J), leading the tuberculosis (TB) focus area strategy team (FAST), and as a member of the GPH executive leadership team. In this role, Cat leads the enterprise TB FAST to deliver on J&J’s aspiration to create a world without tuberculosis through ending mortality from multidrug-resistant tuberculosis.
Cat previously served as global head of strategy and operations for J&J Innovation (JJI). She had responsibility for aligning the World Without Disease Accelerator, Lung Cancer Initiative and JJI organisations to accelerate innovation in order to prevent, intercept and cure disease.
Before this, Cat held the role of vice-president of strategy and external innovation for Janssen Research and Development, the global R&D arm of Janssen Pharmaceutical Companies of Johnson & Johnson. Here, she directed the development of the company’s long-term ‘A World Without Disease’ strategy, focusing on transforming human health.
Additionally, Cat is an Aspen Institute First Mover Fellow and serves as executive sponsor for the university workstream for Women in Science, Technology, Engineering, Math, Manufacturing and Design (WiSTEM2D).